cancer trial update, page-5

One of the cancers revealed by the trial progress report to be a possible target so far is Non Small Cell Lung Cancer .
NSCLC market size . 2billion P.A.? Found this in a review of Bevacizumab(Avastin) It gives an indication of the market size and what Coramsine would have to beat . Remember , the current trial was for patients who had already exhausted the current approved therapies .
<As VEGF mRNA is upregulated in the majority
of human tumours, bevacizumab could be
effective in a wide range of cancers. Data from
Phase II/III studies in non-small-cell lung
cancer (NSCLC) are anticipated in mid-2005.
In a recent Phase II trial in patients with
advanced metastatic NSCLC, the addition of
bevacizumab to standard carboplatin/paclitaxel
chemotherapy produced a significantly
longer time to progression (32.1 versus 18.4
weeks) than chemotherapy alone. Adverse
events included serious tumour-related bleeding
episodes,with squamous cell histology as a
likely risk factor, and further studies have
selected patients with adenocarcinoma only.
Although not ensured, approval of bevacizumab
in the large NSCLC market,which is
anticipated to occur in 2006,would generate a
further US $2 billion per year in sales.>>
http://www.dresources.com/nature/ntr_1204.pdf
Cheers